Ponder B
Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Box 238, Level 3 Lab Block, Hills Road, Cambridge CB2 2QQ, UK.
Science. 1997 Nov 7;278(5340):1050-4. doi: 10.1126/science.278.5340.1050.
Genetic testing for cancer susceptibility is already part of the clinical management of families with some of the well-defined (but uncommon) inherited cancer syndromes. In cases where the risks associated with a predisposing mutation are less certain, or where there is no clearly effective intervention to offer those with a positive result, its use is more controversial. Careful evaluation of costs and benefits, and of the efficacy of interventions in those found to be at risk, is essential and is only just beginning. An immediate challenge is to ensure that both health professionals and the public understand clearly the issues involved.
癌症易感性的基因检测已经成为一些明确界定(但不常见)的遗传性癌症综合征家族临床管理的一部分。在与易感突变相关的风险不太确定的情况下,或者在没有明确有效的干预措施可供检测结果呈阳性者使用的情况下,其应用更具争议性。仔细评估成本和效益,以及对那些被发现处于风险中的人进行干预的效果,至关重要且才刚刚开始。当务之急是确保卫生专业人员和公众都清楚地了解其中涉及的问题。